Treatment of hepatitis C-related kidney disease

Bibliography

• Pol S, Vallet-Pichard A, Corouge M, et al. Hepatitis C: epidemiology, diagnosis, natural history, and therapy. Contrib Nephrol 2012;176:1-9
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Colucci P, Ponticelli C, et al. Kidney and liver involvement in cryoglobulinemia. Semin Nephrol 2002;22:309-18
   PubMed Web of Science ®Google Scholar
• Pascual M, Perrin L, Giostra E, et al. Hepatitis C virus in patients with cryoglobulinemia type II. J Infect Dis 1990;162:567-9
   Google Scholar
• Ferri C, Greco F, Longombardo G, et al. Antibodies to hepatitis C virus in patients with mixed cryoglobulinemia. Arthritis Rheum 1991;34:1606-10
   PubMed Web of Science ®Google Scholar
• Agnello V, Chung R, Kaplan L. A role of hepatitis C infection in type II cryoglobulinemia. N Engl J Med 1992;327:1490-5
   PubMed Web of Science ®Google Scholar
• Cruzado J, Carrera M, Torras J, et al. Hepatitis C virus infection and de novo glomerular lesions in renal allografts. Am J Transplant 2001;1:171-8
   PubMed Web of Science ®Google Scholar
• Roth D, Cirocco R, Zucker K, et al. De novo membrano-proliferative glomerulonephritis in hepatitis C virus-infected renal allograft recipients. Transplantation 1995;59:1676-82
   PubMed Web of Science ®Google Scholar
• Morales J, Pascual-Capdevila J, Campistol J, et al. Membranous glomerulonephritis associated with hepatitis C virus infection in renal transplant patients. Transplantation 1997;63:1634-9
   PubMed Web of Science ®Google Scholar
• Saadoun D, Resche-Rigon M, Thibault V, et al. Antiviral therapy for hepatitis C virus-associated mixed cryoglobulinemia vasculitis. Arthritis Rheum 2006;54:3696-706
   PubMed Web of Science ®Google Scholar
• Ferri C, Sebastiani M, Giuggioli D, et al. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum 2004;33:355-74
   PubMed Web of Science ®Google Scholar
• Kasuno K, Ono T, Matsumori A, et al. Hepatitis C virus-associated tubulo-interstitial injury. Am J Kidney Dis 2003;41:767-75
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Plaisier E, Saadoun D, et al. Hepatitis C virus infection, mixed cryoglobulinemia, and kidney disease. Am J Kidney Dis 2013;61:623-37
   PubMed Web of Science ®Google Scholar
• El-Serag H, Hampel H, Yeh C, et al. Extra-hepatic manifestations of hepatitis C among United States male veterans. Hepatology 2002;36:1439-45
   PubMed Web of Science ®Google Scholar
• Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int 2008;109:S1-99
   Google Scholar
• Fabrizi F, Martin P, Dixit V, et al. Hepatitis C virus infection and kidney disease: a meta-analysis. Clin J Am Soc Nephrol 2012;7:549-57
   PubMed Web of Science ®Google Scholar
• Wyatt C, Malvestutto C, Coca S, et al. The impact of hepatitis C virus co-infection on HIV-related kidney disease: A systematic review and meta-analysis. AIDS 2008;22:1799-807
   PubMed Web of Science ®Google Scholar
• Tarantino A, De Vecchi A, Montagnino G, et al. Renal disease in essential mixed cryoglobulinemia. Long-term follow-up of 44 patients. Q J Med 1981;50:1-30
   PubMedGoogle Scholar
• Tarantino A, Campise M, Banfi G, et al. Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int 1995;47:618-23
   PubMed Web of Science ®Google Scholar
• D’Amico G. Renal involvement in hepatitis C infection: cryoglobulinemic glomerulonephritis. Kidney Int 1998;54:650-71
   PubMed Web of Science ®Google Scholar
• Baid S, Pascual M, Williams W, et al. Renal thrombotic microangiopathy associated with anticardiolipin antibodies in hepatitis C-positive renal allograft recipients. J Am Soc Nephrol 1999;10:146-53
   PubMed Web of Science ®Google Scholar
• Stehman-Breen C, Alpers C, Fleet W, et al. Focal segmental sclerosis among patients infected with HCV. Nephron 1999;81:37-40
   PubMed Web of Science ®Google Scholar
• Markowitz G, Cheng J, Colvin R, et al. Hepatitis C viral infection is associated with fibrillary glomerulonephritis and immunotactoid glomerulopathy. J Am Soc Nephrol 1998;9:2244-52
   PubMed Web of Science ®Google Scholar
• Gilead Sciences, Inc. Harvoni (ledispavir/sofosbuvir 90 mg/400 mg) [product monograph]. 2014. Available from: http://www.gilead.ca/pdf/ca/sovaldi_pm_english.pdf
   Google Scholar
• Gilead Sciences, Inc. Sovaldi (Sofosbuvir) [product monograph]. 2014. Available from: http://www.gilead.ca/pdf/ca/sovaldi_pm_english.pdf
   Google Scholar
• Ribavirin (Professional Patient Advice). Available from: www.drugs.com/ppa/ribavirin.htlm
   Google Scholar
• Pawlotsky JM. Hepatitis C virus: standard-of-Care treatment. In: De Clercq E, Editor Antiviral agents: advances in pharmacology. Elsevier, Inc; San Diego, CA, USA: 2013
   Google Scholar
• Janssen, Inc. Galexos (simeprevir) [product monograph]. 2015. Available from: www.janssen.ca/product/575
   Google Scholar
• AbbVie Corporation. Holkira PAK ombitasvir/paritaprevir/ritonavir (12.5/75/50 mg) and dasabuvir (250 mg) tablets [product monograph]. 2014. Available from: http://www.abbvie.ca/content/dam/abbviecorp/ca/english/docs/HOLKIRA_PAK_P_M_EN.pdf
   Google Scholar
• Johnson R, Gretch D, Couser W, et al. Hepatitis C virus-associated glomerulonephritis: Effect of alpha-interferon therapy. Kidney Int 1994;46:1700-4
   PubMed Web of Science ®Google Scholar
• Misiani R, Bellavita P, Fenili D, et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994;330:751-6
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Bruchfeld A, Mangano S, et al. Interferon therapy for HCV-associated glomerulonephritis: meta-analysis of controlled trials. Int J Artif Organs 2007;30:212-19
   PubMed Web of Science ®Google Scholar
• Yamabe H, Johnson R, Gretch D, et al. Membrano-proliferative glomerulonephritis is associated with HCV infection responsive to interferon-α. Am J Kidney Dis 1995;25:67-9
   PubMed Web of Science ®Google Scholar
• Morosetti M, Sciarra G, Meloni C, et al. Membrano-proliferative glomerulonephritis and hepatitis C: effects of interferon-α therapy on clinical outcome and histological pattern. Nephrol Dial Transplant 1996;11:532-4
   PubMed Web of Science ®Google Scholar
• Gilli P, Stabellini N, Storari A, et al. Effect of human leukocyte-α interferon on cryoglobulinaemic membrano-proliferative glomerulonephritis associated with hepatitis C virus infection. Nephrol Dial Transplant 1996;11:526-8
   PubMed Web of Science ®Google Scholar
• Sarac E, Bastacky S, Johnson J. Response to high-dose interferon-α after failure of standard therapy in membrano-proliferative glomerulonephritis associated with hepatitis C virus infection. Am J Kidney Dis 1997;30:113-15
   PubMed Web of Science ®Google Scholar
• Misiani R, Bellavita P, Baio P, et al. Successful treatment of HCV-associated cryoglobulinemic glomerulonephritis with a combination of interferon-α and ribavirin. Nephrol Dial Transplant 1999;14:1558-60
   PubMed Web of Science ®Google Scholar
• Reed M, Alexander G, Thiru S, et al. Hepatitis C-associated glomerulonephritis- a novel therapeutic approach. Nephrol Dial Transplant 2001;16:869-71
   PubMed Web of Science ®Google Scholar
• Suzuki T, Yonemura K, Miyaji T, et al. Progressive renal failure and blindness due to retinal haemorrhage after interferon therapy for hepatitis C virus-associated membrano-proliferative glomerulonephritis. Intern Med 2001;40:708-12
   PubMed Web of Science ®Google Scholar
• Perez-Calvo J, Lasierra P, Moros M, et al. Role of ribavirin in membrano-proliferative glomerulonephritis associated with hepatitis C virus infection refractory to alpha-interferon. Nephron 2002;92:459-62
   PubMed Web of Science ®Google Scholar
• Guarnieri A, Marazzi F, Giorgi M, et al. Steroids, interferon-α and ribavirin treatment of cryoglobulinemic glomerulonephritis concurrent with HCV infection. Giorn It Nefrol 2002;19:79-81
   PubMedGoogle Scholar
• Lopes E, Valente L, Silva E, et al. Therapy with interferon-α plus ribavirin for membrano-proliferative glomerulonephritis induced by hepatitis C virus. Braz J Infect Dis 2003;7:353-7
   PubMedGoogle Scholar
• Orlent H, Mathot R, Van Bommel E, et al. Peginterferon and dose-titrated ribavirin for hepatitis C-associated nephrotic membrano-proliferative glomerulonephritis type I. Dig Dis Sci 2005;50:1804-6
   PubMed Web of Science ®Google Scholar
• Cua I, Kwan V, Henriquez M, et al. Long-term suppressive therapy with pegylated interferon for chronic hepatitis C associated membrano-proliferative glomerulonephritis. Gut 2006;55:1521-2
   PubMed Web of Science ®Google Scholar
• Koziolek H, Scheel A, Bramlage C, et al. Effective treatment of hepatitis C-associated immune-complex nephritis with cryoprecipitate apheresis and antiviral therapy. Clin Nephrol 2007;67:245-9
   PubMed Web of Science ®Google Scholar
• Ahmed M, Wong C, Shawki H, et al. Rapidly deteriorating renal function with membrano-proliferative glomerulonephritis type 1 associated with hepatitis C treated successfully with steroids and antiviral therapy: a case report and review of the literature. Clin Nephrol 2008;69:298-301
   PubMed Web of Science ®Google Scholar
• Lo K, Chen C, Lee C. Hepatitis C virus-associated type II mixed cryoglobulinemia vasculitis complicated with membranous proliferative glomerulonepritis. Renal Fail 2009;31:149-52
   PubMed Web of Science ®Google Scholar
• Namba T, Shiba R, Yamamoto T, et al. Successful treatment of HCV-related cryoglobulinemic glomerulonephritis with double-filtration plasmapheresis and interferon combination therapy. Clin Exp Nephrol 2010;14:372-6
   PubMed Web of Science ®Google Scholar
• Colucci G, Manno C, Grandaliano G, et al. Cryoglobulinemic membranoproliferative glomerulonephritis: beyond conventional therapy. Clin Nephrol 2011;75:374-9
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Fogazzi G, Cresseri D, et al. Antiviral therapy of HCV-associated cryoglobulinemic glomerulonephritis: Case-report and literature review. Blood Press Kidney Res 2012;35:687-93
   PubMed Web of Science ®Google Scholar
• Stehman-Breen C, Alpers C, Couser W, et al. Hepatitis C virus-associated membranous glomerulonephritis. Clin Nephrol 1995;44:141-7
   PubMed Web of Science ®Google Scholar
• Altraif H, Abdulla A, Al Sebayel M, et al. Hepatitis C associated glomerulonephritis. Am J Nephrol 1995;15:407-10
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Pozzi C, Farina M, et al. Hepatitis C virus infection and acute or chronic glomerulonephritis: an epidemiological and clinical appraisal. Nephrol Dial Transplant 1998;13:1991-7
   PubMed Web of Science ®Google Scholar
• Kiyomoto H, Hitomi H, Hosotani Y, et al. The effect of combination therapy with interferon and cryofiltration on mesangial proliferative glomerulonephritis originating from mixed cryoglobulinemia in chronic hepatitis C virus infection. Ther Apher 1999;3:329-33
   PubMedGoogle Scholar
• Ezaki Y, Tanaka U, Minoshima S, et al. Focal segmental glomerulosclerosis associated with type C virus hepatitis and decrement of proteinuria by interferon-alpha therapy. Nippon Jinzo Gakkai Shi 1999;41:83-8
   PubMedGoogle Scholar
• Al-Wakeel J, Mitwalli A, Tarif N, et al. Role of IFN-α in the treatment of primary glomerulonephritis. Am J Kidney Dis 1999;33:1142-6
   PubMed Web of Science ®Google Scholar
• Laganovic M, Jelakovich B, Kuzmanic D, et al. Complete remission of cryoglobulinemic glomerulonephritis (HCV-positive) after high dose interferon therapy. Wien Klin Wochenschr 2000;112:596-600
   PubMed Web of Science ®Google Scholar
• Motta M, Malaguarnera M, Restuccia N, et al. Focal segmental glomerulosclerosis and hepatitis C virus. Panminerva Med 2001;43:49-52
   PubMed Web of Science ®Google Scholar
• Ji F, Li Z, Ge H, et al. Successful interferon-α treatment in a patient with IgA nephropathy associated with hepatitis C virus infection. Intern Med 2010;49:2531-2
   PubMed Web of Science ®Google Scholar
• Sperati C. Stabilization of hepatitis C-associated collapsing focal segmental glomerulosclerosis with IFN α-2a and ribavirin. Clin Nephrol 2013;80:231-4
   PubMed Web of Science ®Google Scholar
• Shah H, Patel C. Long-term response to peginterferon in hepatitis C virus-associated nephrotic syndrome from focal segmental glomerulosclerosis. Renal Fail 2013;35:1182-5
   PubMed Web of Science ®Google Scholar
• Mazzaro C, Panarello G, Carniello S, et al. Interferon versus steroids in patients with hepatitis C virus-associated cryoglobulinaemic glomerulonephritis. Digest Liver Dis 2000;32:708-15
   Web of Science ®Google Scholar
• Bruchfeld A, Lindahl K, Stahle L, et al. Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. Nephrol Dial Transplant 2003;18:1573-80
   PubMed Web of Science ®Google Scholar
• Rossi P, Bertani T, Baio P, et al. Hepatitis C virus-related cryoglobulinemic glomerulonephritis: Long-term remission after antiviral therapy. Kidney Int 2003;63:2236-41
   PubMed Web of Science ®Google Scholar
• Alric L, Plaisier E, Thebault S, et al. Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis. Am J Kidney Dis 2004;43:617-23
   PubMed Web of Science ®Google Scholar
• Garini G, Allegri L, Iannuzzella F, et al. HCV-related cryoglobulinemic glomerulonephritis: implications of antiviral and immunosuppressive therapies. Acta Biomed 2007;78:51-9
   PubMedGoogle Scholar
• Roccatello D, Fornasieri D, Giachino O, et al. Multicenter study on hepatitis C virus-related cryoglobulinemic glomerulonephritis. Am J Kidney Dis 2007;49:69-82
   PubMed Web of Science ®Google Scholar
• Abbas G, Hussain S, Shafi T. Effect of antiviral therapy on hepatitis C virus related glomerulopathy. Saudi J Kidney Dis Transplant 2008;19:775-80
   PubMedGoogle Scholar
• Dussol B, Moal V, Daniel L, et al. Spontaneous remission of HCV-induced cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant 2001;16:156-9
   PubMed Web of Science ®Google Scholar
• Cruzado J, Gil Vernet S, Ercilla G, et al. Hepatitis C virus-associated membrano-proliferative glomerulonephritis in renal allograft. J Am Soc Nephrol 1996;7:2469-75
   PubMed Web of Science ®Google Scholar
• Davis C, Gretch D, Perkins J, et al. Hepatitis C-associated glomerular disease in liver transplant recipients. Liver Transplant Surg 1995;1:166-75
   PubMedGoogle Scholar
• Montalbano M, Pasulo L, Sonzogni A, et al. Treatment with pegylated interferon and ribavirin for hepatitis C virus-associated severe cryoglobulinemia in a liver/kidney transplant recipient. J Clin Gastroenterol 2007;41:216-20
   PubMed Web of Science ®Google Scholar
• Humphries K, Darling J, Barritt A. Membrano-proliferative glomerulonephritis, type II cryoglobulinemia and triple therapy for hepatitis C: a case series and review of the literature. Dig Dis Sci 2014;59:2007-12
   PubMed Web of Science ®Google Scholar
• Cornella S, Stine G, Kelly V, et al. Persistence of mixed cryoglobulinemia despite cure of hepatitis C with new oral antiviral therapy including direct-acting antiviral sofosbuvir: a new case series. Postgrad Med 2015;127:413-17
   PubMed Web of Science ®Google Scholar
• Saadoun D, Resche-Rigon M, Thibault V, et al. Antiviral therapy for hepatitis C virus-associated mixed cryoglobulinemia vasculitis: a long-term follow-up study. Arthritis Rheum 2006;54:3696-706
   PubMed Web of Science ®Google Scholar
• Saadoun D, Rigon M, Pol S, et al. PegIFNα/ribavirin/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis. J Hepatol 2015;62:24-30
   PubMed Web of Science ®Google Scholar
• Roccatello D, Baldovino S, Rossi D, et al. Rituximab as a therapeutic tool in severe mixed cryoglobulinemia. Clinic Rev Allerg Immunol 2008;34:111-17
   PubMed Web of Science ®Google Scholar
• Quartuccio L, Soardo G, Romano G, et al. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in absence of steroids. Rheumatology 2006;45:842-6
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Martin P, Elli A, et al. Hepatitis C virus infection and rituximab therapy after renal transplantation. Int J Artif Organs 2007;30:445-9
   PubMed Web of Science ®Google Scholar
• Kamar N, Sandres-Saunè K, Rostaing L. Influence of rituximab therapy on hepatitis C virus RNA concentration in kidney-transplant patients. Am J Transplant 2007;7:2440
   PubMed Web of Science ®Google Scholar
• Basse G, Ribes D, Kamar N, et al. Rituximab therapy for de novo mixed cryoglobulinemia in renal transplant patients. Transplantation 2005;80:1560-4
   PubMed Web of Science ®Google Scholar
• Cacoub P, Delluc A, Saadoun D, et al. Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand ? Ann Rheum Dis 2008;67:283-7
   PubMed Web of Science ®Google Scholar
• De Vita S, Quartuccio L, Isola M, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum 2012;64:843-53
   PubMed Web of Science ®Google Scholar
• Sneller M, Hu Z, Langford C. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum 2012;64:835-42
   PubMed Web of Science ®Google Scholar
• Saadoun D, Resche Rigon M, Sene D, et al. Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood 2010;116:326-34
   PubMed Web of Science ®Google Scholar
• Dammacco F, Tucci F, Lauletta G, et al. Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixec cryoglobulinemia: a long-term study. Blood 2010;116:343-53
   PubMed Web of Science ®Google Scholar
• Patterson J, Fernandez-Larsson R. Molecular mechanisms of action of ribavirin. Rev Infect Dis 1990;12:1139-46
   PubMedGoogle Scholar
• Kamar N, Izopet J, Tripon S, et al. Ribavirin for chronic hepatitis E virus infection in transplant recipients. N Engl J Med 2014;370:1111-20
   PubMed Web of Science ®Google Scholar
• Del Bello A, Guilbeau-Frugier C, Josse A, et al. Successful treatment of hepatitis E virus–associated cryoglobulinemic membrano-proliferative glomerulonephritis with ribavirin. Transplant Infect Dis 2015;17:279-83
   PubMed Web of Science ®Google Scholar
• Pham H, Feray C, Samuel D, et al. Effects of ribavirin on hepatitis C-associated nephrotic syndrome in four liver transplant recipients. Kidney Int 1998;54:1311-19
   PubMed Web of Science ®Google Scholar
• Hu S, Jaber B. Ribavirin mono-therapy for hepatitis C virus-associated membranous nephropathy. Clin Nephrol 2005;63:41-5
   PubMed Web of Science ®Google Scholar
• Kamar N, Sandres-Saune K, Selves J, et al. Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: effects on renal function and liver histology. Am J Kidney Dis 2003;42:184-92
   PubMed Web of Science ®Google Scholar
• Durand J, Cacoub P, Lunel-Fabiani F, et al. Ribavirin in hepatitis C related cryoglobulinemia. J Rheumatol 1998;25:1115-17
   PubMed Web of Science ®Google Scholar
• Donato F, Fabrizi F, Fogazzi G, et al. Remission of HCV-associated glomerulonephritis with pegylated interferon and ribavirin after liver transplantation: case report and literature review. Int J Artif Organs 2013;36:63-8
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Messa P, Martin P. Novel evidence on hepatitis C virus-associated glomerular disease. Kidney Int 2014;86:466-9
   PubMed Web of Science ®Google Scholar